9 May 2023: Aker BioMarine ASA (the "Company") has renewed its offer of new shares to employees in the Company and its Norwegian subsidiaries on similar terms as for 2022 (the "Employee Share Purchase Program"). The deadline for acceptance of the offer in the Employee Share Purchase Program expired today, on 9 May 2023, at 16:30 CET.
The offer price for the shares in the Employee Share Purchase Program has been set to approximately NOK 29,81 (the "Offer Price"). The Offer Price is based on the volume-weighted average share price for the Company's shares on the Oslo Stock Exchange during the last five trading days prior to, and including, the last day of the application period, with a discount of 20%. Any shares acquired in the Employee Share Purchase Program will be subject to a lock-up period of two years, and the reduced offer price shall reflect the value-reducing effect of the lock-up period.
Based on the applications received in the Employee Share Purchase Program, the board of directors of the Company has allocated a total of 35,015 new shares to the participants in the Employee Share Purchase Program (the "Program Shares").
Furthermore, the board of directors has, on the basis of the authorisation granted to it by the annual general meeting held on 20 April 2023, resolved to increase the share capital of the Company with NOK 210 090, by issuance of 35,015 new shares, each with a nominal value of NOK 6.00, at a subscription price equal to the Offer Price. The Program Shares comprise approximately 0.04% of the existing and outstanding shares in the Company prior to their issuance.
Following the registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret), the new share capital of the Company will be NOK 526 036 488, divided into 87 672 748 shares, each with a nominal value of NOK 6.00.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
For further information, please contact
Katrine Klaveness, CFO
Mobile: +47 991 58 915
Email: Katrine.Klaveness@akerbiomarine.com
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.